Evidence map›Paper›PMID 30455201›Full record

ArticleInfection and immunity2019

PPE37 Is Essential for

Michael V Tullius, Susana Nava, Marcus A Horwitz

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 47 citations in OpenAlex.

  1. ThemBio · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. The PE/PPE family proteins ofFrontiers in immunology · 2025
    Review
  9. Article
  10. Review
  11. Impact of MSMEG5257 Deletion onMicroorganisms · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Pirates of the haemoglobin.Microbial cell (Graz, Austria) · 2022
    Review
  19. Article
  20. Frontiers in immunology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Michael V TulliusDivision of Infectious Diseases, Department of Medicine, Center for Health Sciences, School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Susana NavaDivision of Infectious Diseases, Department of Medicine, Center for Health Sciences, School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Marcus A HorwitzDivision of Infectious Diseases, Department of Medicine, Center for Health Sciences, School of Medicine, University of California-Los Angeles, Los Angeles, California, USA mhorwitz@mednet.ucla.edu.
University of California, Los Angeles · US

Funding

Optimization and Advanced Proof-of-Concept Studies of a Listeria-vectored Multi-Antigenic Vaccine against TuberculosisR01AI135631 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HORWITZ, MARCUS AARON · 2018 to 2022
$5.5M
NIAID NIH HHS R01 AI135631
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bacterial ProteinsBCG VaccineDNA, BacterialHemeIron-Binding ProteinsMembrane ProteinsMycobacterium bovisMycobacterium tuberculosisSequence Analysis, DNASequence DeletionTuberculosisTuberculosis VaccinesVirulenceBacterial ProteinsBCG VaccineDNA, BacterialHemeIron-Binding ProteinsMembrane ProteinsPPE37 protein, Mycobacterium tuberculosisTuberculosis VaccinesBCGhemeheminironMycobacterium bovisMycobacterium tuberculosismycobactinsiderophoreTween 80tyloxapol

Identifiers

PMID30455201
PMCPMC6346139
OpenAlexW2900568125

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.